Angiogenesis and metastasis

European Journal of Cancer Part A

Volumn 32, Issue 14, 1996, Pages 2451-2460

  Ellis, L M ^a   Fidler, I J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BASIC FIBROBLAST GROWTH FACTOR; BETA INTERFERON; GAMMA INTERFERON;

ANGIOGENESIS; GENE EXPRESSION; HUMAN; IN SITU HYBRIDIZATION; METASTASIS; PRIORITY JOURNAL; REVIEW; TUMOR CELL;

EID: 0030498734     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00389-9     Document Type: Article

References (119)

1. 1. Fidler IJ. Critical factors in the biology of human cancer metastasis: Twenty-eighth G.H.A. Clowes Memorial Award Lecture. Cancer Res 1990, 50, 6130-6138.
2. 2. Sugarbaker EV. Cancer metastasis: a product of tumor-host interactions. Curr Probl Cancer 1979, 3, 1-59.
3. 3. Weiss L. Principles of Metastasis. Orlando, Academic Press, 1985.
4. 4. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes Memorial Award Lecture. Cancer Res 1986, 46, 467-473.
5. 5. Fidler IJ, Ellis LM. The implications of angiogenesis to the biology and therapy of cancer metastasis. Cell 1994, 79, 185-188.
6. 6. Liotta LA, Steeg PS, Stetlet-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991, 64, 327-336.
7. 7. Takahashi Y, Bucana CD, Liu W, et al. Platelet derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells. J Natl Cancer Inst 1996, 88, 1146-1151.
8. 8. Fidler IJ. Modulation of the organ microenvironment for treatment of cancer metastasis. J Natl Cancer Inst 1995, 87, 1588-1592.
9. 9. Dvorak HF. Tumors: wounds that do not heal. N Engl J Med 1986, 315, 1650-1659.
10. 10. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1995, 1, 27-31.
11. 11. Auerbach W, Auerbach R. Angiogenesis inhibition: a review. Pharmacol Ther 1994, 63, 265-311.
12. 12. Folkman J, Klagsburn M. Angiogenic factors (Review). Science 1987, 235, 442-447.
13. 13. Folkman J, Cotran R. Relation of vascular proliferation to tumor growth. Int Rev Exp Pathol 1976, 16, 207-248.
14. 14. Liotta LA, Kleinerman J, Saidel GM. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res 1974, 34, 997-1003.
15. 15. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast cancer. N Engl J Med 1991, 324, 1-8.
16. 16. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992, 84, 1875-1887.
17. 17. Gasparini G, Fox SB, Verderio P, et al. Determination of angiogenesis adds information to estrogen receptor status in predicting the efficacy of adjuvant tamoxifen in node-positive breast cancer patients. Clin Cancer Res 1996, 2, 1191-1198.
18. 18. Obermair A, Czerwenka K, Kurz C, Kaider A, Sevelda P. Tumoral vascular density in breast tumors and their effect on recurrence-free survival. Chirurg 1994, 65, 611-615.
19. 19. Toi M, Kashitani J, Tominaga T. Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma. Int J Cancer 1993, 55, 371-374.
20. 20. Visscher DW, Smilanetz S, Drozdowicz S, Wykes SM. Prognostic significance of image morphometric microvessel enumeration in breast carcinoma. Anal Quant Cytol Histol 1993, 15, 88-92.
21. 21. Horak ER, Leek R, Klenk N, et al. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as an indicator of node metastases and survival in breast cancer. Lancet 1992, 340, 1120-1124.
22. 22. Bosari S, Lee AKC, DeLellis RA, Wiley BD, Heatley GJ, Silverman ML. Microvessel quantitation and prognosis in invasive breast carcinoma. Human Pathol 1992, 23, 755-761.
23. 23. Hall N, Fish D, Hunt N, Goldin R, Guillou P, Monson J. Is the relationship between angiogenesis and metastasis in breast cancer real? Surg Oncol 1992, 1, 223-229.
24. 24. Van Hoef ME, Knox WF, Dhesi SS, Howell A, Schor AM. Assessment of tumour vascularity as a prognostic factor in lymph node negative invasive breast cancer. Eur J Cancer 1993, 29A, 1141-1145.
25. 25. Axelsson K, Ljung BM, Moore II DH, et al. Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J Natl Cancer Inst 1995, 87, 997-1008.
26. 26. Weidner N, Carroll PR, Flax J, Flumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993, 143, 401-409.
27. 27. Graham CH, Rivers J, Kerbel RS, Stankiewicz KS, White WL. Extent of vascularization as a prognostic indicator in thin (<0.76 mm) malignant melanomas. Am J Pathol 1994, 145, 510-514.
28. 28. Hollingsworth HC, Kohn EC, Steinberg SM, Rothenberg ML, Meriono MJ. Tumor angiogenesis in advanced stage ovarian carcinoma. Am J Pathol 1995, 147, 33-41.
29. 29. Maeda K, Chung YS, Takatsuka S, et al. Tumour angiogenesis and tumour cell proliferation as prognostic indicators in gastric carcinoma. Br J Cancer 1995, 72, 319-323.
30. 30. Takahashi Y, Cleary KR, Mai M, Kitadai Y, Bucana CD, Ellis LM. Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. Clin Cancer Res 1996, 2, 1679-1684.
31. 31. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995, 55, 3964-3968.
32. 32. Ellis LM, Fidler IJ. Angiogenesis and breast cancer metastasis. Lancet 1995, 346, 388-389.
33. 33. Fidler IJ. Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res 1978, 38, 2651-2660.
34. 34. Fidler IJ, Hart IR. Biological diversity in metastatic neoplasms: origins and implications. Science 1982, 217, 998-1003.
35. 35. Heppner G. Tumor heterogeneity. Cancer Res 1984, 44, 2259-2265.
36. 36. Hart IR, Goode NT, Wilson RE. Molecular aspects of the metastatic cascade. Biochim Biophys Acta 1989, 989, 65-84.
37. 37. Liotta LA, Stetler-Stevenson WG. Tumor invasion and metastasis: an imbalance of positive and negative regulation (Review). Cancer Res 1991, 51, 5054s-5059s.
38. 38. Poste G, Fidler IJ. The pathogenesis of cancer metastasis. Nature 1979, 283, 139-146.
39. 39. Kitadai Y, Ellis LM, Takahashi Y, et al. Multiparametric in situ mRNA hybridization analysis to detect metastasis-related genes in surgical specimens of human colon carcinomas. Clin Cancer Res 1995, 1, 1095-1102.
40. 40. Singh RK, Bucana CD, Gutman M, Fan D, Wilson MR, Fidler IJ. Organ site-dependent expression of basic fibroblast growth factor in human renal cell carcinoma cells. Am J Pathol 1994, 145, 365-374.
41. 41. Fidler IJ, Gersten DM, Hart IR. The biology of cancer invasion and metastasis. Adv Cancer Res 1978, 28, 149-250.
42. 42. O'Reilly MS, Homgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994, 79, 315-328.
43. 43. Sidky YA, Auerbach R. Lymphocyte-induced angiogenesis in tumor-bearing mice. Science 1976, 192, 1237-1238.
44. 44. Meininger CJ, Zetter BR. Mast cells and angiogenesis. Semin Cancer Biol 1992, 3, 73-79.
45. 45. Fidler IJ. Lymphocytes are not only immunocytes (guest editorial). Biomedicine 1980, 32, 1-3.
46. 46. Fidler IJ, Gersten DM, Kripke ML. Influence of immune status on the metastasis of three murine fibrosarcomas of different immunogenicities. Cancer Res 1979, 39, 3816-3821.
47. 47. Miguez M, Davel L, deLustig ES. Lymphocyte-induced angiogenesis: correlation with the metastatic incidence of two murine mammary adenocarcinomas. Invasion Metastasis 1986, 6, 313-320.
48. 48. Freeman MR, Schneck FX, Gagnon ML, et al. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Res 1995, 55, 4140-4145.
49. 49. Polverini P, Cotran R, Gimbrone N, Unanue E. Activated macrophages induce vascular proliferation. Nature 1977, 269, 804-805.
50. 50. Sunderkötter C, Steinbrink K, Goebeler M, Bhardwaj R, Sorg C. Macrophages and angiogenesis. J Leukocyte Biol 1994, 55, 410-422.
51. 51. Leek RD, Harris AL, Lewis CE. Cytokine networks in solid human tumors: regulation of angiogenesis. J Leukocyte Biol 1994, 56, 423-435.
52. 52. Srivastava A, Laidler P, Davies RP, Morgan K, Hughes LE. The prognostic significance of tumor vascularity in intermediate thickness (0.76-4.0 mm thick) skin melanoma: a quantitative histologic study. Am J Pathol 1988, 133, 419-423.
53. 53. Smolle J, Soyer HP, Hoffman-Wellenhof R, Smolle-Juettner FM, Kerl H. Vascular architecture of melanocytic skin tumors. Pathol Res Pract 1989, 185, 740-745.
54. 54. Ruiter DJ, Bhan AK, Harris TJ, Sober AJ, Mihm Jr MC. Major histocompatibility antigens and the mononuclear inflammatory infiltrate in benign nevomelanocytic proliferation and malignant melanoma. J Immunol 1982, 129, 2808-2815.
55. 55. Klausner JM, Gutman M, Inbar M, Rozin RR. Unknown primary melanoma. J Surg Oncol 1983, 24, 129-131.
56. 56. Brocker EG, Rechenbeld C, Hamm H, Ruiter DJ, Sorg C. Macrophages in melanocytic naevi. Arch Dermatol Res 1992, 284, 127-131.
57. 57. DiPietro LA, Polverini PJ. Angiogenic macrophages produce the angiogenic inhibitor thrombospondin 1. Am J Pathol 1993, 143, 678-684.
58. 58. Rappolee DA, Mark D, Banda MJ, Werb Z. Wound macrophages express TGF-α and other growth factors in vivo: analysis by mRNA phenotyping. Science 1988, 241, 708-712.
59. 59. Fumagalli U, Trabucchi E, Soligo M, et al. Effects of intraperitoneal chemotherapy on anastomotic healing in the rat. J Sur Res 1991, 50, 82-87.
60. 60. Noh R, Karp GI, Devereaux DF. The effect of doxorubicin and mitoxanthrone on wound healing. Cancer Chemother Pharmacol 1991, 29, 141-144.
61. 61. Hendricks T, Martens MF, Huyben CM, Wobbes T. Inhibition of basal and TGF-β-induced fibroblast collagen synthesis by antineoplastic agents: implications for wound healing. Br J Cancer 1993, 67, 545-550.
62. 62. Fidler IJ, Gersten DM. Effect of syngeneic lymphocytes on the vascularity, growth, and induced metastasis of the B16 melanoma. In Crispen R, ed. Neoplasm Immunity: Experimental and Clinical. New York/Elsevier, North Holland Publishing Company, 1980, 3-15.
63. 63. Gutman M, Singh RK, Yoon S, Xie K, Bucana CD, Fidler IJ. Leukocyte-induced angiogenesis and subcutaneous growth of B16 melanoma. Cancer Biother 1994, 9, 163-170.
64. 64. Dameron KM, Volpert OV, Tainsky MA, Bouk N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994, 265, 1502-1504.
65. 65. Ueba T, Nosaka T, Takahashi JA, et al. Transcriptional regulation of basic fibroblast growth factor gene by p53 in human glioblastoma and hepatocellular carcinoma cells. Proc Natl Acad Sci USA 1994, 91, 9009-9013.
66. 66. Kieser A, Weich HA, Brandner G, Marme D, Kolch W. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor. Oncogens 1994, 9, 963-969.
67. 67. Singh RK, Llansa N, Bucana CD, Sanchez R, Fidler IJ. Cell density-dependent modulation of basic FGF by interferon-beta (abstract). Proc Am Assoc Cancer Res 1995, 36, 87.
68. 68. Takahashi K, Mulligan JB, Kozakewich HPW, Rogers RA, Folkman J, Ezekowitz RAB. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest 1994, 93, 2357-2364.
69. 69. Ezekowitz RAB, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992, 326, 1456-1463.
70. 70. Singh R, Gutman M, Bucana CD, Sanchez R, Llansa N, Fidler IJ. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA 1995, 92, 4562-4566.
71. 71. Brown LF, Berse B, Jackman RW, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 1993, 53, 4727-4735.
72. 72. Brown LF, Berse B, Jackman RW, et al. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol 1993, 143, 1255-1262.
73. 73. Shweiki D, Itin A, Stoffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992, 359, 843-845.
74. 74. Shima DT, Deutsch U, D'Amore PA. Hypoxic induction of vascular endothelial growth factor (VEGF) in human epithelial cells is mediated by increases in mRNA stability. FEBS Lett 1995, 370, 203-208.
75. 75. Ikeda E, Achen MG, Breier G, Risau W. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem 1995, 34, 19761-19768.
76. 76. Levy AP, Levy NS, Wegner S, Goldberg MA. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem 1995, 270, 13333-13340.
77. 77. Koochekpour S, Merzak A, Pilkington GJ. Vascular endothelial growth factor production is stimulated in response to growth factors in human glioma cells. Oncology Reports 1995, 2, 1059-1061.
78. 78. Stavri GT, Hong Y, Zachary IC, et al. Hypoxia and platelet-derived growth factor-BB synergistically upregulate the expression of vascular endothelial growth factor in vascular smooth muscle cells. FEBS Lett 1995, 358, 311-315.
79. 79. Tsai JC, Goldman CK, Gillespie GY. Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDGF-BB, and bFGF. J Neurosurg 1995, 82, 864-873.
80. 80. Silvagno F, Follenzi A, Arese M, et al. In vivo activation of met tyrosine kinase by heterodimeric hepatocyte growth molecule promotes angiogenesis. Arteriosclerosis, Thrombosis & Vascular Biol 1995, 15, 1857-1865.
81. 81. Detmar M, Yeo KT, Nagy JA, et al. Keratinocyte-derived vascular permeability factor (vascular endothelial growth factor) is a potent mitogen for dermal microvascular endothelial cells. J Invest Dermatol 1995, 105, 44-50.
82. 82. Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 1996, 271, 736-741.
83. 83. Li J, Perrella MA, Tsai JC, et al. Induction of vascular endothelial growth factor gene expression by interleukin-1β in rat aortic smooth muscle cells. J Biol Chem 1995, 270, 308-312.
84. 84. Pertovaara L, Kaipainen A, Mustonen T, et al. Vascular endothelial growth factor is induced in response to transforming growth factor-β in fibroblastic and epithelial cells. J Biol Chem 1994, 269, 6271-6274.
85. 85. Koura AN, Radinsky R, Kitadai Y, et al.. Regulation of vascular endothelial growth factor expression in human colon carcinoma cells by cell density. Cancer Res, in press.
86. 86. Mukhopadhyay D, Tsiokas L, Zhou XM, Foster D, Brugge JS, Sukhatme VP. Hypoxic induction of human vascular endothelial growth factor expression through c-src activation. Nature 1995, 375, 577-581.
87. 87. Mukhopadhyay D, Tsiokas L, Sukhatme VP. Wild-type p53 and v-src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res 1995, 55, 6161-6165.
88. 88. Rak J, Mitsuhashi Y, Bayko L, et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res (Adv in Brief) 1995, 55, 4575-4580.
89. 89. Rak J, Filmus J, Finkenzeller G, Grugel S, Marine D, Kerbel RS. Oncogenes as inducers of tumor angiogenesis. Cancer Met Rev 1995, 14, 263-277.
90. 90. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889, 1, 571-573.
91. 91. Gutman M, Singh RK, Xie K, Bucana CD, Fidler IJ. Regulation of interleukin-8 expression in human melanoma cells by the organ environment. Cancer Res 1995, 55, 2470-2475.
92. 92. Gutman M, Singh RK, Bucana CD, Fidler IJ. Expression of IL-8 in human melanoma cells with different metastatic potential growing in different organ environments. Proc Am Assoc Cancer Res 1994, 35, 57 (abstract 340).
93. 93. Takahashi Y, Mai M, Wilson MR, Kitadai Y, Bucana CD, Ellis LM. Site-dependent expression of vascular endothelial growth factor, angiogenesis and proliferation in human gastric carcinoma. Int J Oncol 1996, 8, 701-705.
94. 94. Fidler IJ, Poste G. The cellular heterogeneity of malignant neoplasms: implications for adjuvant chemotherapy. Semin Oncol 1985, 12, 207-221.
95. 95. Kitadai Y, Ellis LM, Tucker SL, et al. Multiparametric in situ mRNA hybridization analysis to predict disease recurrence in patients with colon carcinoma. Am J Pathol, in press.
96. 96. Weidner N, Carroll PR, Flax J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Path 1993, 143, 401-409.
97. 97. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast cancer. N Engl J Med 1991, 324, 1-8.
98. 98. Weidner N. Tumor angiogenesis: review of current applications in tumor prognostication. New Cancer Strategies: Angiogenesis Antagonists. Washington, DC, Cambridge Healthtech Institute, 1995.
99. 99. Takahashi Y, Fidler IJ, Kitadai Y, Bucana CD, Cleary K, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995, 55, 3964-3968.
100. 100. Macchiarini P, Fontanini G, Hardin M, Squartini F, Angeletti C. Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet 1992, 340, 145-146.
101. 101. Mattern J, Koomägi R, Volm M. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br J Cancer 1996, 73, 931-934.
102. 102. Gasparini G, Weidner N, Bevilacqua P, et al. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 1994, 12, 454-466.
103. 103. Gasparini G, Harris AL. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol 1995, 13, 765-782.
104. 104. Gasparini G, Weidner N, Bevilacqua P. Intratumoral microvessel density and p53 protein: correlation with metastasis in head-and-neck squamous-cell carcinoma. Int J Cancer 1993, 55, 739-744.
105. 105. Goulding H, Rashid NFNA, Robertson JF, et al. Assessment of angiogenesis in breast carcinoma: an important factor in prognosis? Human Pathol 1995, 26, 1196-1200.
106. 106. Ohsawa M, Tomita Y, Kuratsu S, Kanno H, Aozasa K. Angiogenesis in malignant fibrous histiocytoma. Oncology 1995, 52, 51-54.
107. 107. Fidler IJ, Balch CM. The biology of cancer metastasis and implications for therapy. Curr Probl Surg 1987, 24, 137-208.
108. 108. Angeletti CA, Lucchi M, Fontanini G, et al. Prognostic significance of tumoral angiogenesis in completely resected late stage lung carcinoma (Stage IIIA-N2): impact of adjuvant therapies in a subset of patients at high risk of recurrence. Cancer 1996, 78, 409-415.
109. 109. Gasparini G, Barbareschi M, Boracchi P, et al. Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy. Cancer J Sci Am 1995, 1, 131-141.
110. 110. Chen C, Parangi S, Tolentino MJ, Folkman J. A strategy to discover circulating angiogenesis inhibitors generated by human tumors. Cancer Res 1995, 55, 4230-4233.
111. 111. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994, 91, 4082-4085.
112. 112. Folkman J, Ingber D. Inhibition of angiogenesis. Cancer Biol 1992, 3, 89-96.
113. 113. Ito K, Abe T, Tomita M, et al. Anti-angiogenic activity of arachidonic acid metabolism inhibitors in angiogenesis model systems involving human microvascular endothelial cells and neovascularization in mice. Int J Cancer 1993, 55, 660-666.
114. 114. Marshall JL, Hawkins MJ. The clinical experience with anti-angiogenic agents. Breast Cancer Res Treat 1995, 36, 253-261.
115. 115. Scott PAE, Harris AL. Current approaches to targeting cancer using antiangiogenesis therapies. Cancer Treat Rev 1994, 20, 393-412.
116. 116. Teicher BA, Holden SA, Ara G, et al. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int J Cancer 1994, 57, 920-925.
117. 117. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995, 87, 581-586.
118. 118. Yamaoka M, Yamamoto T, Ikeyama S, Sudo K, Fujita T. Angiogenesis inhibitor TNP-40 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines. Cancer Res 1993, 53, 5233-5236.
119. 119. Fidler IJ. Molecular biology of cancer: invasion and metastasis. In De Vita JR, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Philadelphia, Lippincott-Raven, 1997, 135-152.